

**STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.**

ATTORNEYS AT LAW  
1100 NEW YORK AVENUE, N.W., SUITE 600  
WASHINGTON, D.C. 20005-3934

RECEIVED/8  
AUG 6 0 1999

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. EDMOND  
TRACY-GENE G. DURKIN  
MICHELE A. CIMBALA  
MICHAEL B. RAY  
ROBERT E. SOKOHL

ERIC K. STEFFE  
MICHAEL Q. LEE  
STEVEN R. LUDWIG  
JOHN M. COVERT\*  
LINDA E. ALCORN  
RAZ E. FLESHER  
ROBERT C. MILLONIG  
MICHAEL V. MESSINGER  
JUDITH U. KIM  
TIMOTHY J. SHEA, JR.

DONALD R. MCPHAIL  
PATRICK E. GARRETT  
STEPHEN G. WHITESIDE  
JEFFREY T. HELVEY\*  
HEIDI L. KRAUS  
JEFFREY R. KURIN  
RAYMOND MILLIEN  
PATRICK D. O'BRIEN  
LAWRENCE B. BUGAISKY  
CRYSTAL D. SAYLES\*

EDWARD W. YEE  
ALBERT L. FERRO\*  
DONALD R. BANOWITZ\*  
PETER A. JACKMAN  
MOLLY A. MCCALL  
TERESA U. MEDLER  
JEFFREY S. WEAVER  
KRISTIN K. VIDOVICH  
ANDREW S. ROBERTS\*  
KENDRICK P. PATTERSON\*

DONALD J. FEATHERSTONE\*\*  
KAREN R. MARKOWICZ\*\*  
GRANT E. REED\*\*  
SUZANNE E. ZISKA\*\*  
BRIAN J. DEL BUONO\*\*  
VINCENT L. CARUANO\*\*  
ANDREA J. KAMAGE\*\*  
NANCY J. DEGEN\*\*  
  
ROBERT H. BENSON\*  
OF COUNSEL

\*BAR OTHER THAN D.C.

\*\*REGISTERED PATENT AGENTS



August 17, 1999

WRITER'S DIRECT NUMBER: (202) 371-2625

INTERNET ADDRESS: ESTEFFE@SKGF.COM

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 08/935,377; Filed: September 22, 1997  
For: **T Cells Specific for Target Antigens and Vaccines Based Thereon**  
Inventor: Zauderer, M.  
Our Ref: 1821.0010000/EKS/CMB

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement and Statement Under 37 C.F.R. § 1.97(e)(1) (in duplicate);
2. Form PTO-1449 (2 pages);
3. Copies of references AA1, AL1, AM1, AN1, AO1, AR1, AS1, AT1, AR2, and AS2; and
4. A return postcard.


Assistant Commissioner for Patents  
August 17, 1999  
Page 2

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe  
Attorney for Applicant  
Registration No. 36,688

Enclosures

#  
13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZAUDERER, M.

Appl. No. 08/935,377

Filed: September 22, 1997

Art Unit: 1618

Examiner: Wessendorf, T.

Atty. Docket: 1821.0010000/EKS/CMB



For: **T Cells Specific for Target  
Antigens and Vaccines Based  
Thereon**

**First Supplemental Information Disclosure Statement  
and Statement Under 37 C.F.R. § 1.97(e)(1)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is submitted herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This First Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date but before the mailing date of the first Office Action on the merits.

I hereby state that each item of information contained in this First Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe  
Attorney for Applicant  
Registration No. 36,688

Date: 8/10/99

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600